What Integro Theranostics does

Integro Theranostics is a clinical-stage private biotechnology company developing an intraoperative molecular imaging (IMI) platform to help surgeons visualize cancer in real time during tumor resection surgery. The platform is built around two co-developed core products: Cronexitide Lanocianine (CXL, formerly LS301), a fluorescent imaging agent consisting of a small peptide conjugated to a near-infrared dye that binds to activated Annexin A2 protein expressed on cancer cells, and the CancerVision Goggles, a wearable head-mounted mixed-reality display that overlays CXL fluorescence signals onto the surgeon's natural-color field of view. Together, these products are designed to enable identification of cancer margins, microscopic tumors, and sentinel lymph nodes that are invisible to the naked eye, with the explicit goal of reducing positive margins and repeat surgeries.

The technology stack is anchored by Dr. Samuel Achilefu's research at Washington University School of Medicine's Mallinckrodt Institute, Molecular Imaging Center, and Siteman Cancer Center, and now extends to UT Southwestern Medical Center where Dr. Achilefu serves as inaugural Chair of Biomedical Engineering. An AI/analytics layer is layered on top through a partnership with OmniScience, providing computer vision workflows for deep tissue and intraoperative pathology assessment, predictive analytics for cancer spread, and data-driven clinical decision support across pre-, intra-, and post-operative imaging. The company holds 65 U.S. patents covering both the imaging agent and the wearable display, with CXL currently advancing through a Phase II lung cancer study initiated in late 2025 after positive Phase 1b results (NCT05900986 covers an ongoing breast cancer Phase 1b/2).

Integro Theranostics is a portfolio company of Kingdom Capital, a values-driven private investment firm whose founder Dave Steward also chairs World Wide Technology. The company's primary customer segments are hospitals and surgical centers performing cancer resection surgery, with secondary exposure to oncology clinical trial sponsors via the OmniScience AI tooling. Forward-looking revenue mechanics consist of single-use CXL imaging agent sales on a per-procedure basis paired with reusable CancerVision Goggles hardware sales to healthcare institutions, though no commercial pricing is disclosed and the company is not yet generating revenue. Strategic communications are concentrated in scientific publications, surgical and oncology conferences, and targeted press releases rather than consumer marketing channels.

Name

Integro Theranostics

Legal name

Integro Theranostics

Website

https://integrotheranostics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Integro Theranostics is a clinical-stage biotech developing an intraoperative molecular imaging platform for cancer surgery, combining the CXL fluorescent imaging agent, CancerVision Goggles, and AI analytics to help surgeons visualize tumors in real time.

Ownership category

akta.pro rank

Product category

Surgical Imaging Agents and Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity) (HLAHADAE)

Keywords

• Intraoperative molecular imaging
• Fluorescent cancer imaging
• Surgical imaging agents
• Augmented reality surgery
• Fluorescence-guided oncology

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. CXL Fluorescent Imaging Agent: Cronexitide Lanocianine (CXL) is administered to patients prior to surgery, providing a single-use per procedure revenue stream. The imaging agent is supplied to hospitals and surgical centers as a pharmaceutical product integrated into surgical care workflows.
2. CancerVision Goggles: Wearable medical device sold to hospitals and surgical centers for use in cancer surgery. Provides reusable hardware revenue opportunity alongside consumable imaging agent sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Integro Theranostics develops an intraoperative molecular imaging (IMI) platform combining a fluorescent imaging agent (Cronexitide Lanocianine, CXL) with a wearable augmented reality display (CancerVision Goggles) and AI-powered analysis tools. The platform enables surgeons to visualize cancer cells, tumor margins, and lymph nodes in real time during oncologic surgery, particularly for lung and breast cancer procedures.

Product overview

Integro Theranostics is a clinical-stage company developing an intraoperative molecular imaging (IMI) platform for cancer surgery guidance. The platform combines two core products: CXL (Cronexitide Lanocianine), a fluorescent imaging agent that binds to and illuminates cancer tissue when exposed to near-infrared light, and the proprietary CancerVision Goggles, a wearable augmented reality display that visualizes the fluorescent signal overlaid on natural color imagery during surgery. Together, these products enable surgeons to identify cancer margins and lymph nodes in real-time, improving precision and completeness of tumor resection. The company also offers AI-powered solutions developed in partnership with OmniScience for computer vision-based cancer detection and clinical decision support.

Differentiator

Problem solved

Functional benefit

Brands

• CXL (Cronexitide Lanocianine): A novel fluorescing molecule that binds to and illuminates cancer tissue, formerly known as LS301. A targeted fluorescent imaging agent for intraoperative molecular imaging during cancer surgery.
• CancerVision Goggles

Products and services

• CXL (Cronexitide Lanocianine) Fluorescent Imaging Agent A novel fluorescent imaging agent consisting of a small peptide and near-infrared (NIR) dye that binds to the activated form of Annexin A2 on cancer cells, enabling real-time visualization of tumors, cancer margins, and lymph nodes during oncologic surgery. Administered to patients prior to surgery and supplied to hospitals and surgical centers as a single-use pharmaceutical per procedure.
• CancerVision Goggles A wearable head-mounted mixed reality display system that overlays CXL fluorescence images onto the surgeon's natural color field of view in real time. Enables surgeons to visualize cancer cells, identify microscopic tumors, assess surgical margins, and identify sentinel lymph nodes during cancer resection surgery without disrupting operating room workflow.
• AI-Powered Clinical Decision Support Solutions AI-powered computer vision workflows developed in partnership with OmniScience that enable deep tissue analysis at gross and microscopic scales, fluorescence characterization of tissue types, intraoperative pathology assessment, pattern identification, and predictive analytics for cancer clinical trials. Aggregates pre-, intra-, and post-operative imaging data to deliver data-driven clinical decision support.

Quantifiable outcome

• 48% of 23 patients in Phase 1b study had previously undetected or unseen cancer lesions (Clinically Significant Events) identified using CXL
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Washington University School of MedicinecoreStrategic or Co-development PartnerIntegro Theranostics was born out of collaboration between Kingdom Capital and Washington University School of Medicine. Dr. Achilefu developed CXL and CancerVision Goggles technology at Washington University's Mallinckrodt Institute, Molecular Imaging Center, and Siteman Cancer Center.
• OmniSciencecoreTechnology or IntegrationPartnership to optimize cancer clinical trials using AI-powered computer vision workflows. OmniScience is developing advanced analytics for deep tissue analysis at gross and microscopic scales and fluorescence characterization of tissue types. The collaboration enables intraoperative pathology assessment through computer vision.
• World Wide Technology (WWT)supportingTechnology or IntegrationWorld Wide Technology, the largest Black-owned company in the U.S., is supporting Integro's technology needs through software, cloud computing, and data resources. WWT is founded by Dave Steward, who also chairs Kingdom Capital.
• UT Southwestern Medical CentersupportingStrategic or Co-development PartnerDr. Samuel Achilefu serves as the inaugural Chair of the Department of Biomedical Engineering at UT Southwestern Medical Center, where he continues research activities while serving as Integro's Chief Scientific Officer.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Perimeter Medical Imaging AI: Developer of OTIS (Optical Coherence Tomography Imaging System) for intraoperative margin assessment during breast-conserving surgery. Addresses the same surgical margin problem as Integro via a complementary imaging modality.
• Lumicell: Developer of Lumisight (pegulicianine), an FDA-approved fluorescent imaging agent for breast cancer lumpectomy margin assessment. Most direct competitor to Integro's CXL, addressing the same intraoperative cancer visualization problem in an overlapping indication.
• On Target Laboratories: Developer of Cytalux (pafolacianine), an FDA-approved fluorescent imaging agent targeting folate receptor-expressing cancers including ovarian and lung. Directly comparable to CXL as a targeted fluorescent agent for intraoperative cancer visualization.
• Blaze Bioscience: Developer of Tumor Paint (BLZ-100), a tumor-targeted fluorescent imaging agent for fluorescence-guided cancer surgery. Competes in the same intraoperative molecular imaging category as Integro's CXL platform.

Emerging players

• Medivis: Developer of augmented reality surgical visualization platforms for use in operating rooms. Overlaps with Integro's CancerVision Goggles in wearable AR-mediated surgical guidance, though Medivis focuses on anatomical rather than fluorescent visualization.
• Surgical Theater: Provider of VR/AR-based surgical visualization and planning tools. Adjacent competitor in immersive surgical visualization technology with overlapping enterprise hospital sales channels.
• Activ Surgical: Developer of ActivSight intraoperative imaging software providing real-time visual overlays of perfusion and other tissue characteristics. An emerging adjacent player in AR/computer-vision-enhanced surgery with comparable design intent to CancerVision Goggles.
• Elucent Medical: Developer of intraoperative surgical guidance and soft-tissue marker systems for oncology procedures, including breast and soft-tissue tumor localization. Compares to Integro on the broader theme of improving surgical precision in cancer resection workflows.

Broad incumbents

• Intuitive Surgical: Manufacturer of the Da Vinci surgical robot with integrated Firefly fluorescence imaging. Represents a broad incumbent in fluorescence-guided minimally invasive surgery whose installed base shapes how new agents like CXL gain OR access.
• Stryker: Large medtech incumbent offering SPY-PHI and SPY-Fi fluorescence imaging systems integrated into surgical workflows across multiple specialties. Competes broadly in fluorescence-guided surgery infrastructure that may be used alongside or against agent-based approaches like Integro's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/integro-theranostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integro Theranostics